Positive phase IIb data for BAF312 (siponimod) in MS

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.

Positive phase IIb data for BAF312 (siponimod) in MS

Postby MSUK » Fri Apr 20, 2012 3:35 am


At the 64th annual meeting of the American Academy of Neurology (AAN) Novartis will present the key results from a phase II dose finding study of its investigational compound BAF312 (siponimod), a selective modulator of the S1P receptor subtypes 1 and 5 (S1P1, 5-R modulator), in MS.

This double-blind placebo-controlled study applied an innovative adaptive trial design to optimally describe the dose response relationship.

A statistically significant dose response relationship could be established....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397
MS-UK - http://www.ms-uk.org/
User avatar
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 3:00 pm


Return to General Discussion


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service